Oxford BioMedica PLC (LSE:OXB) - Share price

Stock Report

Oxford BioMedica PLC OXB

Last Price

Day Change

As of 11/08/2022
10:05:09 BST | GBX
Minimum 15 Minutes Delay.

Last Close489.00p
Day Range487.60 - 505.00
Mkt Cap469.80Mil
52-Wk Range414.00 - 1,678.00
Yield %-

Share Price

Total Returns 10/08/2022

 Chg (%)  
More ...
Oxford BioMedica PLC-0.81 
FTSE 100 TR GBP4.50
More ...
Income Statement
Operating Profit-12.58-4.8620.93
Net Profit-16.07-6.2519.01
Reported EPS-22.10-7.8122.20
Balance Sheet
Current Assets56.94107.95163.84
Non Current Assets65.9975.9873.39
Total Assets122.93183.93237.23
Current Liabilities28.9452.4633.31
Total Liabilities47.3071.1849.89
Total Equity75.63112.75187.34
Cash Flow
Operating Cash Flow-6.64-3.8924.46
Net Change in Cash-16.0030.5062.20
Director Dealings
More ...
29/04/2022PurchaseMs. Catherine Moukheibir570.902,46714,084.00
21/04/2022PurchaseDr. Roch F. Doliveux589.3358,219343,102.00
21/04/2022PurchaseMr. Stuart Henderson589.201,0005,892.00
20/04/2022PurchaseDr. Roch F. Doliveux536.2029,000155,498.00

Company Profile

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focusses on the field of immunotherapy by managing a platform of technologies in designing gene-based medicines. The company operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of revenue from Europe.




FTSE SmallCap , FTSE All Share , FTSE techMARK Focus , FTSE techMARK All Share

Next Event 22/09/2022

Half-Yearly Results
More ...
PER (E)21.76
Div Yld (E)0.00
PEG (E)0.00
Op Mrgn0.15
EPS Grwth0.00
More ...
Record Datet.b.c.t.b.c.
More ...
Executive Director, Chief Executive OfficerMr. John Andrew Dawson CBE
Executive Director, Chairman and Chief Executive Officer (Interim)Dr. Roch F. Doliveux
Non-Executive DirectorDr. Michael Hayden, Ch.B.,M.B.,PhD
Non-Executive DirectorDr. Heather Elizabeth Preston
Non-Executive Director, Senior Independent Director Deputy ChairmanMr. Stuart Henderson
Executive Director, Chief Financial OfficerMr. Stuart Paynter
Non-Executive DirectorMs. Catherine Moukheibir
Non-Executive DirectorDr. Siyamak Rasty
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.